U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.12
    +0.48 (+1.05%)
     
  • Gold

    1,841.40
    +0.30 (+0.02%)
     
  • Silver

    24.30
    +0.16 (+0.65%)
     
  • EUR/USD

    1.2121
    -0.0028 (-0.2303%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • Vix

    20.79
    -0.49 (-2.30%)
     
  • GBP/USD

    1.3433
    -0.0019 (-0.1424%)
     
  • USD/JPY

    104.1880
    +0.3280 (+0.3158%)
     
  • BTC-USD

    18,811.24
    -146.77 (-0.77%)
     
  • CMC Crypto 200

    368.29
    -10.95 (-2.89%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences

·1 min read

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows:

Jefferies Virtual London Healthcare Conference
Wednesday, November 18, 2020, 1:10pm EST (Fireside Chat)
Presenters: John Fowler, Chief Executive Officer; Christopher Kirk, PhD, Chief Scientific Officer, and Noreen R. Henig, MD, Chief Medical Officer

2020 Evercore ISI HealthCONx Conference
Thursday, December 3, 2020, 1:00pm EST (Presentation)
Presenter: John Fowler, Chief Executive Officer

The presentations will be webcast live and may be accessed in the "Investors and News" section of the Company’s website at www.kezarlifesciences.com. Kezar Life Sciences will maintain an archived replay of the webcasts on its website for 90 days after the conference.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction, and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112006003/en/

Contacts

Celia Economides
IR@kezarbio.com